The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
Hypertension as Cardiovascular Risk Factor in Chronic Kidney Disease
Abstract
Hypertension is the leading modifiable cause of premature death and hence one of the global targets of World Health Organization for prevention. Hypertension also affects the great majority of patients with chronic kidney disease (CKD). Both hypertension and CKD are intrinsically related, as hypertension is a strong determinant of worse renal and cardiovascular outcomes and renal function decline aggravates hypertension. This bidirectional relationship is well documented by the high prevalence of hypertension across CKD stages and the dual benefits of effective antihypertensive treatments on renal and cardiovascular risk reduction. Achieving an optimal blood pressure (BP) target is mandatory and requires several pharmacological and lifestyle measures. However, it also requires a correct diagnosis based on reliable BP measurements (eg, 24-hour ambulatory BP monitoring, home BP), especially for populations like patients with CKD where reduced or reverse dipping patterns or masked and resistant hypertension are frequent and associated with a poor cardiovascular and renal prognosis. Even after achieving BP targets, which remain debated in CKD, the residual cardiovascular risk remains high. Current antihypertensive options have been enriched with novel agents that enable to lower the existing renal and cardiovascular risks, such as SGLT2 (sodium-glucose cotransporter-2) inhibitors and novel nonsteroidal mineralocorticoid receptor antagonists. Although their beneficial effects may be driven mostly from actions beyond BP control, recent evidence underline potential improvements on abnormal 24-hour BP phenotypes such as nondipping. Other promising novelties are still to come for the management of hypertension in CKD. In the present review, we shall discuss the existing evidence of hypertension as a cardiovascular risk factor in CKD, the importance of identifying hypertension phenotypes among patients with CKD, and the traditional and novel aspects of the management of hypertensives with CKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Bikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O. M., Afarideh, M., Agarwal, S. K., Agudelo-Botero, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30045-3 · Cited by 6,648
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Alonso, A., Beaton, A. Z., Bittencourt, M. S., Boehme, A. K., Buxton, A. E., Carson, A. P., Commodore-Mensah, Y., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001052 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
New creatinine- and cystatin C-based equations to estimate GFR without race
Inker, L. A., Eneanya, N. D., Coresh, J., Tighiouart, H., Wang, D., Sang, Y., Crews, D. C., Doria, A., Estrella, M. M., Froissart, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102953 · Cited by 4,695
(2010) · The Lancet · doi:10.1016/s0140-6736(10)60674-5 · Cited by 4,200 · cited 1×
“67 In addition, patients with CKD often cumulate several other risk factors, such as diabetes, obesity, and dyslipidemia, and finally, CKD-specific risk factors accumulate as kidney diseases worsen.”
The global epidemiology of hypertension
Mills, K. T., Stefanescu, A., & He, J. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0244-2 · Cited by 4,133
2020 International Society of Hypertension Global Hypertension Practice Guidelines
Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15026 · Cited by 4,132 · cited 1×
“65,66,92 In addition to RAS blockers, guidelines also recommend the use of calcium antagonists and diuretics preferentially as dual or triple single-pill combinations with RAS blockers.”
Estimating glomerular filtration rate from serum creatinine and cystatin C
Inker, L. A., Schmid, C. H., Tighiouart, H., Eckfeldt, J. H., Feldman, H. I., Greene, T., Kusek, J. W., Manzi, J., Van Lente, F., Zhang, Y. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114248 · Cited by 4,102
Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis
Hill, N. R., Fatoba, S. T., Oke, J. L., Hirst, J. A., O’Callaghan, C. A., Lasserson, D. S., & Hobbs, F. D. R. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158765 · Cited by 4,030
Zhou, B., Carrillo-Larco, R. M., Danaei, G., Riley, L. M., Paciorek, C. J., Stevens, G. A., Gregg, E. W., Bennett, J. E., Solomon, B., Singleton, R. K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01330-1 · Cited by 3,902 · cited 1×
“5,19,20 23 Data from observational studies have shown that death from both coronary heart disease and stroke increases exponentially from BP levels as low as 115 mm Hg systolic and 75 mm Hg diastolic upward and the risk is present in all age groups between 40 and >80 years of age.”
Epidemiology of chronic kidney disease: an update 2022
Kovesdy, C. P. (2022) · Kidney International Supplements · doi:10.1016/j.kisu.2021.11.003 · Cited by 2,973
Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate
Stevens, L. A., Coresh, J., Greene, T., & Levey, A. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra054415 · Cited by 2,952
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001940 · Cited by 2,885
Self-citationEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Zhou, B., Bentham, J., Di Cesare, M., Bixby, H., Danaei, G., Cowan, M. J., Paciorek, C. J., Singh, G., Hajifathalian, K., Bennett, J. E., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31919-5 · Cited by 2,579
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
Gansevoort, R. T., Correa-Rotter, R., Hemmelgarn, B. R., Jafar, T. H., Heerspink, H. J. L., Mann, J. F., Matsushita, K., & Wen, C. P. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60595-4 · Cited by 2,213 · cited 2×
“13 One of them is the fact that a low eGFR and albuminuria per se are associated with an increased risk of cardiovascular morbidity and mortality independently of traditional risk factors.”
Impact of High-Normal Blood Pressure on the Risk of Cardiovascular Disease
Vasan, R. S., Larson, M. G., Leip, E. P., Evans, J. C., O'Donnell, C. J., Kannel, W. B., & Levy, D. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003417 · Cited by 2,082
High blood pressure and cardiovascular disease
Fuchs, F. D., & Whelton, P. K. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.14240 · Cited by 1,948
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Blood Pressure and End-Stage Renal Disease in Men
Klag, M. J., Whelton, P. K., Randall, B. L., Neaton, J. D., Brancati, F. L., Ford, C. E., Shulman, N. B., & Stamler, J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340103 · Cited by 1,663
Cheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Hou, F. F., Ix, J. H., Knoll, G. A., Muntner, P., Pecoits-Filho, R., Sarnak, M. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.11.003 · Cited by 1,452
Agarwal, R., Filippatos, G., Pitt, B., Anker, S. D., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Gebel, M., Ruilope, L. M., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab777 · Cited by 1,317 · cited 2×
“108 Finerenone also improved heart failure outcomes irrespective of baseline eGFR or UACR categories, thus confirming the role of aldosterone antagonists in the management of heart failure.”
Sotagliflozin in patients with diabetes and chronic kidney disease
Bhatt, D. L., Szarek, M., Pitt, B., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Inzucchi, S. E., Kosiborod, M. N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030186 · Cited by 1,205
Sympathetic Overactivity in Patients with Chronic Renal Failure
Converse, R. L., Jacobsen, T. N., Toto, R. D., Jost, C. M. T., Cosentino, F., Fouad-Tarazi, F., & Victor, R. G. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272704 · Cited by 1,132 · cited 1×
“…CKD. 96 Nevertheless, when considering the upregulation of sympathetic nervous system in CKD, associated with an increased risk of cardiovascular events and renal disease progression, 97 there is still a D o w n l o a d e d fr o m h tt p :// a h a j ou r n a l s . o r g by on A p r il 17 , 2023”
Prognostic Value of Ambulatory Blood-Pressure Recordings in Patients with Treated Hypertension
Clement, D. L., De Buyzere, M. L., De Bacquer, D. A., de Leeuw, P. W., Duprez, D. A., Fagard, R. H., Gheeraert, P. J., Missault, L. H., Braun, J. J., Six, R. O., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022273 · Cited by 1,085
Baigent, C., Emberson, J., Haynes, R., Herrington, W. G., Judge, P., Landray, M. J., Mayne, K. J., Ng, S. Y. A., Preiss, D., Roddick, A. J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02074-8 · Cited by 1,020
Stergiou, G. S., Palatini, P., Parati, G., O’Brien, E., Januszewicz, A., Lurbe, E., Persu, A., Mancia, G., Kreutz, R., & on behalf of the European Society of Hypertension Council and the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002843 · Cited by 859
Bobrie, G. (2004) · JAMA · doi:10.1001/jama.291.11.1342 · Cited by 842
Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension
Zhang, W., Zhang, S., Deng, Y., Wu, S., Ren, J., Sun, G., Yang, J., Jiang, Y., Xu, X., Wang, T.-D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2111437 · Cited by 784
Bakris, G. L., Agarwal, R., Chan, J. C., Cooper, M. E., Gansevoort, R. T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R. E., Nowack, C., et al. (2015) · JAMA · doi:10.1001/jama.2015.10081 · Cited by 708
Del Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02188-7 · Cited by 684
Wheeler, D. C., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., McMurray, J. J. V., Correa-Rotter, R., Rossing, P., Toto, R. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30369-7 · Cited by 556
van den Hoogen, P. C. W., Feskens, E. J. M., Nagelkerke, N. J. D., Menotti, A., Nissinen, A., & Kromhout, D. (2000) · New England Journal of Medicine · doi:10.1056/nejm200001063420101 · Cited by 552
Hsu, C.-Y., McCulloch, C. E., Darbinian, J., Go, A. S., & Iribarren, C. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.8.923 · Cited by 473
Wanner, C., Lachin, J. M., Inzucchi, S. E., Fitchett, D., Mattheus, M., George, J., Woerle, H. J., Broedl, U. C., von Eynatten, M., & Zinman, B. (2018) · Circulation · doi:10.1161/circulationaha.117.028268 · Cited by 469
Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial
Hermida, R. C., Crespo, J. J., Domínguez-Sardiña, M., Otero, A., Moyá, A., Ríos, M. T., Sineiro, E., Castiñeira, M. C., Callejas, P. A., Pousa, L., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz754 · Cited by 467
Wheeler, D. C., Toto, R. D., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., McMurray, J. J. V., Pecoits-Filho, R., Correa-Rotter, R., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.033 · Cited by 420
Management of Hypertension in Chronic Kidney Disease
Pugh, D., Gallacher, P. J., & Dhaun, N. (2019) · Drugs · doi:10.1007/s40265-019-1064-1 · Cited by 401
Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension
Freeman, M. W., Halvorsen, Y.-D., Marshall, W., Pater, M., Isaacsohn, J., Pearce, C., Murphy, B., Alp, N., Srivastava, A., Bhatt, D. L., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2213169 · Cited by 395
Hodgkinson, J., Mant, J., Martin, U., Guo, B., Hobbs, F. D. R., Deeks, J. J., Heneghan, C., Roberts, N., & McManus, R. J. (2011) · BMJ · doi:10.1136/bmj.d3621 · Cited by 370 · cited 1×
“46 Several studies have demonstrated that patients may be misclassified as normotensive or hypertensive when considering only clinic BP. 53,63,64 In the context of CKD, this may have important clinical implications not only to assess the prevalence of hypertension in the population but also to…”
Liu, J. E., Roman, M. J., Pini, R., Schwartz, J. E., Pickering, T. G., & Devereux, R. B. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-8-199910190-00003 · Cited by 354
Blood Pressure Predicts Risk of Developing End-Stage Renal Disease in Men and Women
Tozawa, M., Iseki, K., Iseki, C., Kinjo, K., Ikemiya, Y., & Takishita, S. (2003) · Hypertension · doi:10.1161/01.hyp.0000069699.92349.8c · Cited by 352
Risk of developing end-stage renal disease in a cohort of mass screening
Iseki, K., Iseki, C., Ikemiya, Y., & Fukiyama, K. (1996) · Kidney International · doi:10.1038/ki.1996.111 · Cited by 342
The Economic Burden of Chronic Kidney Disease and End-Stage Renal Disease
Wang, V., Vilme, H., Maciejewski, M. L., & Boulware, L. E. (2016) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2016.05.008 · Cited by 316
Heerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Tuttle, K. R., & Cherney, D. Z. I. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00243-1 · Cited by 306
Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease
Agarwal, R., Sinha, A. D., Cramer, A. E., Balmes-Fenwick, M., Dickinson, J. H., Ouyang, F., & Tu, W. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110730 · Cited by 292
Minutolo, R., Agarwal, R., Borrelli, S., Chiodini, P., Bellizzi, V., Nappi, F., Cianciaruso, B., Zamboli, P., Conte, G., Gabbai, F. B., et al. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.230 · Cited by 287
Pogue, V., Rahman, M., Lipkowitz, M., Toto, R., Miller, E., Faulkner, M., Rostand, S., Hiremath, L., Sika, M., Kendrick, C., et al. (2009) · Hypertension · doi:10.1161/hypertensionaha.108.115154 · Cited by 282
Bedtime Dosing of Antihypertensive Medications Reduces Cardiovascular Risk in CKD
Hermida, R. C., Ayala, D. E., Mojón, A., & Fernández, J. R. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011040361 · Cited by 269
Agarwal, R., & Andersen, M. J. (2006) · Kidney International · doi:10.1038/sj.ki.5000247 · Cited by 252
Schlaich, M. P., Bellet, M., Weber, M. A., Danaietash, P., Bakris, G. L., Flack, J. M., Dreier, R. F., Sassi-Sayadi, M., Haskell, L. P., Narkiewicz, K., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02034-7 · Cited by 248
Mackenzie, I. S., Rogers, A., Poulter, N. R., Williams, B., Brown, M. J., Webb, D. J., Ford, I., Rorie, D. A., Guthrie, G., Grieve, J. W. K., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01786-x · Cited by 240
Cardiovascular Protection Using Beta-Blockers
Bangalore, S., Messerli, F. H., Kostis, J. B., & Pepine, C. J. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.04.060 · Cited by 233
SGLT2 Inhibitor–Induced Sympathoinhibition
Herat, L. Y., Magno, A. L., Rudnicka, C., Hricova, J., Carnagarin, R., Ward, N. C., Arcambal, A., Kiuchi, M. G., Head, G. A., Schlaich, M. P., et al. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.11.007 · Cited by 233
Cardiovascular risk factors in chronic kidney disease
Menon, V., Gul, A., & Sarnak, M. J. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00551.x · Cited by 206
Baker, W. L., Buckley, L. F., Kelly, M. S., Bucheit, J. D., Parod, E. D., Brown, R., Carbone, S., Abbate, A., & Dixon, D. L. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005686 · Cited by 204
Drawz, P. E., Alper, A. B., Anderson, A. H., Brecklin, C. S., Charleston, J., Chen, J., Deo, R., Fischer, M. J., He, J., Hsu, C.-Y., et al. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08530815 · Cited by 199
Thomas, G., Xie, D., Chen, H.-Y., Anderson, A. H., Appel, L. J., Bodana, S., Brecklin, C. S., Drawz, P., Flack, J. M., Miller, E. R., et al. (2016) · Hypertension · doi:10.1161/hypertensionaha.115.06487 · Cited by 190
Predictors of new-onset decline in kidney function in a general middle-european population
Obermayr, R. P., Temml, C., Knechtelsdorfer, M., Gutjahr, G., Kletzmayr, J., Heiss, S., Ponholzer, A., Madersbacher, S., Oberbauer, R., & Klauser-Braun, R. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm790 · Cited by 184
Control of Hypertension in Adults With Chronic Kidney Disease in the United States
Peralta, C. A., Hicks, L. S., Chertow, G. M., Ayanian, J. Z., Vittinghoff, E., Lin, F., & Shlipak, M. G. (2005) · Hypertension · doi:10.1161/01.hyp.0000164577.81087.70 · Cited by 182
The 2017 Clinical Practice Guideline for High Blood Pressure
Whelton, P. K., & Carey, R. M. (2017) · JAMA · doi:10.1001/jama.2017.18209 · Cited by 178
All-cause costs increase exponentially with increased chronic kidney disease stage.
Golestaneh, L., Alvarez, P. J., Reaven, N. L., Funk, S. E., McGaughey, K. J., Romero, A., Brenner, M. S., & Onuigbo, M. A. C. (2017) · PubMed · Cited by 173
Novel non‐steroidal mineralocorticoid receptor antagonists in cardiorenal disease
Kintscher, U., Bakris, G. L., & Kolkhof, P. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15747 · Cited by 173
Prevalence of Apparent Treatment-Resistant Hypertension among Individuals with CKD
Tanner, R. M., Calhoun, D. A., Bell, E. K., Bowling, C. B., Gutiérrez, O. M., Irvin, M. R., Lackland, D. T., Oparil, S., Warnock, D., & Muntner, P. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00550113 · Cited by 168
Fliser, D., Schröter, M., Neubeck, M., & Ritz, E. (1994) · Kidney International · doi:10.1038/ki.1994.298 · Cited by 165
Farmer, C. (1997) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/12.11.2301 · Cited by 164
Stage IV Chronic Kidney Disease
Abboud, H., & Henrich, W. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmcp0906797 · Cited by 163
Sim, J. J., Shi, J., Kovesdy, C. P., Kalantar-Zadeh, K., & Jacobsen, S. J. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.04.065 · Cited by 160
Prevalence, Causes, and Consequences of Masked Hypertension: A Meta-analysis
Verberk, W. J., Kessels, A. G. H., & de Leeuw, P. W. (2008) · American Journal of Hypertension · doi:10.1038/ajh.2008.221 · Cited by 159
Mojón, A., Ayala, D. E., Piñeiro, L., Otero, A., Crespo, J. J., Moyá, A., Bóveda, J., de Lis, J. P., Fernández, J. R., Hermida, R. C., et al. (2012) · Chronobiology International · doi:10.3109/07420528.2012.703083 · Cited by 159
de la Sierra, A., Gorostidi, M., Banegas, J. R., Segura, J., de la Cruz, J. J., & Ruilope, L. M. (2013) · American Journal of Hypertension · doi:10.1093/ajh/hpt175 · Cited by 149
Spotlight on CKD deaths—increasing mortality worldwide
Rhee, C. M., & Kovesdy, C. P. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.25 · Cited by 148
Garofalo, C., Borrelli, S., Pacilio, M., Minutolo, R., Chiodini, P., Nicola, L. D., & Conte, G. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.08.027 · Cited by 141
Wheeler, D. C., Jongs, N., Stefánsson, B. V., Chertow, G. M., Greene, T., Hou, F. F., Langkilde, A. M., McMurray, J. J. V., Rossing, P. R., Nowicki, M. P., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab335 · Cited by 138
Masked Hypertension and White-Coat Hypertension in Chronic Kidney Disease: A Meta-analysis
Bangash, F., & Agarwal, R. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05391008 · Cited by 134
Mancia, G., Cannon, C. P., Tikkanen, I., Zeller, C., Ley, L., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07703 · Cited by 128 · cited 1×
“In their analysis, Mancia et al 136 studied the changes in ambulatory BP induced by empagliflozin from baseline to week 12 in patients receiving 0, 1, or ≥ 2 antihypertensive medications as well as in patients receiving diuretics or RAS blockers.”
Zhou, B., Bentham, J., Cesare, M. D., Bixby, H., Danaei, G., Hajifathalian, K., Taddei, C., Carrillo-Larco, R. M., Djalalinia, S., Khatibzadeh, S., et al. (2018) · International Journal of Epidemiology · doi:10.1093/ije/dyy016 · Cited by 126
Minutolo, R., Gabbai, F. B., Agarwal, R., Chiodini, P., Borrelli, S., Bellizzi, V., Nappi, F., Stanzione, G., Conte, G., & Nicola, L. D. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.06.014 · Cited by 124
Smink, P. A., Heerspink, H. J. L., Gansevoort, R. T., de Jong, P. E., Hillege, H. L., Bakker, S. J. L., & de Zeeuw, D. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.06.017 · Cited by 119
Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes
Ruilope, L. M., Agarwal, R., Anker, S. D., Filippatos, G. S., Pitt, B., Rossing, P. R., Sarafidis, P. A., Schmieder, R. E., Joseph, A., Rethemeier, N., et al. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.19744 · Cited by 118
Agarwal, R., & Andersen, M. J. (2006) · American Journal of Nephrology · doi:10.1159/000097366 · Cited by 117
Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes
Agarwal, R., Ruilope, L. M., Ruiz‐Hurtado, G., Haller, H. G., Schmieder, R. E., Anker, S. D., Filippatos, G. S., Pitt, B., Rossing, P. R., Lambelet, M., et al. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003330 · Cited by 117
Martínez‐Castelao, A., Górriz, J. L., Portolés, J. M., de Álvaro, F., Cases, A., Luño, J., Navarro‐González, J. F., Montes, R., de la Cruz, J. J., Natarajan, A., et al. (2011) · BMC Nephrology · doi:10.1186/1471-2369-12-53 · Cited by 113
Empagliflozin and major renal outcomes in heart failure
Packer, M., Butler, J., Zannad, F., Pocock, S. J., Filippatos, G., Ferreira, J. P., Brueckmann, M., Jamal, W., Zeller, C., Wanner, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2112411 · Cited by 112
Heerspink, H. J. L., Cherney, D. Z. I., Postmus, D., Stefánsson, B. V., Chertow, G. M., Dwyer, J. P., Greene, T., Kosiborod, M., Langkilde, A. M., McMurray, J. J. V., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.09.005 · Cited by 99
Masked Uncontrolled Hypertension in CKD
Agarwal, R., Pappas, M. K., & Sinha, A. D. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015030243 · Cited by 98
Gorostidi, M., Sarafidis, P. A., de la Sierra, A., Segura, J., de la Cruz, J. J., Banegas, J. R., & Ruilope, L. M. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.03.025 · Cited by 96
Bakris, G. L., Ruilope, L. M., Anker, S. D., Filippatos, G. S., Pitt, B., Rossing, P. R., Fried, L. P., Roy‐Chaudhury, P., Sarafidis, P. A., Ahlers, C., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.08.040 · Cited by 95
Ghatage, T., Goyal, S., Dhar, A., & Bhat, A. (2021) · Hypertension Research · doi:10.1038/s41440-021-00643-z · Cited by 94
Relationship between Ambulatory BP and Clinical Outcomes in Patients with Hypertensive CKD
Gabbai, F. B., Rahman, M., Hu, B., Appel, L. J., Charleston, J. B., Contreras, G. N., Faulkner, M. L., Hiremath, L., Jamerson, K., Lea, J. P., et al. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11301111 · Cited by 92
Filippatos, G. S., Anker, S. D., Pitt, B., Rossing, P. R., Joseph, A., Kolkhof, P., Lambelet, M., Lawatscheck, R., Bakris, G. L., Ruilope, L. M., et al. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.07.013 · Cited by 91
MATSUI, Y., Eguchi, K., Ishikawa, J., Hoshide, S., SHIMADA, K., & Kario, K. (2007) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2006.10.008 · Cited by 87
Borrelli, S., Garofalo, C., Gabbai, F. B., Chiodini, P., Signoriello, S., Paoletti, E., Ravera, M., Bussalino, E., Bellizzi, V., Liberti, M. E., et al. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2022.04.010 · Cited by 86
Dussol, B., Moussi‐Francès, J., Morange, S., Somma-Delpéro, C., MUNDLER, O., & Berland, Y. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00564.x · Cited by 85
Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition
Lytvyn, Y., Kimura, K. A., Peter, N., LAI, V. S., TSE, J. M., Cham, L., Perkins, B. A., Soleymanlou, N., & Cherney, D. Z. I. (2022) · Circulation · doi:10.1161/circulationaha.122.059150 · Cited by 81
Patients With Renal Dysfunction Require a Longer Duration Until Blood Pressure Dips During the Night
Fukuda, M., Mizuno, M., Yamanaka, T., Motokawa, M., Shirasawa, Y., Nishio, T., Miyagi, S., Yoshida, A., & Kimura, G. (2008) · Hypertension · doi:10.1161/hypertensionaha.108.115329 · Cited by 79
Stergiou, G. S., Brunström, M., MacDonald, T. M., Kyriakoulis, K. G., Bursztyn, M., Khan, N. A., Bakris, G. L., Κόλλιας, Α., Menti, A., Muntner, P., et al. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003240 · Cited by 79
Delanaye, P., Schaeffner, E., Cozzolino, M., Langlois, M., Plebani, M., Ozben, T., & Cavalier, E. (2022) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm-2022-0928 · Cited by 78
Blood Pressure Goals in Patients with CKD: A Review of Evidence and Guidelines
Chang, A. R., Lóser, M. K., Malhotra, R., & Appel, L. J. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07440618 · Cited by 71
Lee, H., Kwon, S. H., Jeon, J. S., Noh, H., Han, D. C., & Kim, H. (2021) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.21.099 · Cited by 70
Clinical Correlates of Ambulatory BP Monitoring among Patients with CKD
Iimuro, S., Imai, E., Watanabe, T., Nitta, K., Akizawa, T., Matsuo, S., Makino, H., Ohashi, Y., & Hishida, A. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06470612 · Cited by 69
Abnormalities in ambulatory blood pressure monitoring in hypertensive patients with diabetes
on behalf of the Spanish Society of Hypertension ABPM Registry investigators, Gorostidi, M., de la Sierra, A., Albarrán, O. G., Segura, J., de la Cruz, J. J., Vinyoles, E., Llisterri, J. L., Aranda, P., Ruilope, L. M., et al. (2011) · Hypertension Research · doi:10.1038/hr.2011.100 · Cited by 61
Sternlicht, H., & Bakris, G. L. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0920-4 · Cited by 60
Kreutz, R. H., Kjeldsen, S. E., Burnier, M., Narkiewicz, K., Oparil, S., & Mancia, G. (2020) · Blood Pressure · doi:10.1080/08037051.2020.1747696 · Cited by 56
Self-citationTsai, W.-C., Hsu, S.-P., Chiu, Y.-L., Yang, J.-Y., Pai, M.-F., Ko, M.-J., Tu, Y.-K., Hung, K.-Y., Chien, K.-L., Peng, Y.-S., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-060655 · Cited by 53
Renal Sodium Handling and Nighttime Blood Pressure
Burnier, M., Coltamai, L., Maillard, M. P., & Bochud, M. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.07.007 · Cited by 52
Self-citationde Beus, E., Bots, M. L., van Zuilen, A. D., Wetzels, J. F. M., & Blankestijn, P. J. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.05694 · Cited by 50
Burnier, M., Kreutz, R. H., Narkiewicz, K., Kjeldsen, S. E., Oparil, S., & Mancia, G. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002532 · Cited by 49
Self-citationDrawz, P. E., Brown, R. Z., Nicola, L. D., Fujii, N., Gabbai, F. B., Gassman, J., He, J., Iimuro, S., Lash, J. P., Minutolo, R., et al. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.13181117 · Cited by 48
Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease
Smeijer, J. D., Kohan, D. E., Webb, D. J., et al. (2021) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000716 · Cited by 48
Wang, C., Zhang, J., Li, Y., Ma, X., Ye, Z., Peng, H., & Lou, T. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.12.105 · Cited by 44
Cao, H., Rao, X., Jia, J., Yan, T., & Li, D. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01989-7 · Cited by 44
Kanno, A., Metoki, H., Kikuya, M., Terawaki, H., Hara, A., Hashimoto, T., Asayama, K., Inoue, R., Shishido, Y., Nakayama, M., et al. (2010) · Hypertension Research · doi:10.1038/hr.2010.139 · Cited by 43
Schneider, M. P., Hilgers, K. F., Schmid, M. C., Hübner, S., Nadal, J., Seitz, D., Busch, M., Haller, H. G., Köttgen, A., Kronenberg, F., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202604 · Cited by 43
Hypertension in Chronic Kidney Disease (CKD): Diagnosis, Classification, and Therapeutic Targets
Georgianos, P. I., & Agarwal, R. (2020) · American Journal of Hypertension · doi:10.1093/ajh/hpaa209 · Cited by 39
Garrison, S., Kolber, M. R., Allan, G. M., Bakal, J. A., Green, L. A., Singer, A. G., Trueman, D. R., McAlister, F. A., Padwal, R. S., Hill, M. D., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-059711 · Cited by 39
Fu, X., Ren, H., Xie, J., Wang, W., Li, Y., Gao, P., & Chen, N. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.14460 · Cited by 36
Masked Hypertension in CKD: Increased Prevalence and Risk for Cardiovascular and Renal Events
Babu, M., & Drawz, P. E. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1154-4 · Cited by 35
Furtado, R. H. M., Raz, I., Goodrich, E. L., Murphy, S. A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., Aylward, P. E., Dalby, A. J., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.058103 · Cited by 34
Role of hypertension in kidney transplant recipients
Loutradis, C., Sarafidis, P. A., Marinaki, S., Berry, M., Borrows, R., Sharif, A., & Ferro, C. J. (2021) · Journal of Human Hypertension · doi:10.1038/s41371-021-00540-5 · Cited by 31
Pisano, A., Mallamaci, F., D’Arrigo, G., Bolignano, D., Wuerzner, G., Ortíz, A., Burnier, M., Kanaan, N., Sarafidis, P. A., Persu, A., et al. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab135 · Cited by 31
Self-citationYan, Z., Wang, Y., Li, S., Wang, J., Zhang, L., Tan, H., Li, S., Yang, L., Pei, H., Zhang, L., et al. (2018) · American Journal of Hypertension · doi:10.1093/ajh/hpx222 · Cited by 30
BP Measurement Techniques: What They Mean for Patients with Kidney Disease
Thomas, G., & Drawz, P. E. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12551117 · Cited by 27
Blood pressure control in patients with chronic kidney disease
Lee, J. Y., & Han, S. H. (2021) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2021.181 · Cited by 26
Böhm, M., Fitchett, D., Ofstad, A. P., Brueckmann, M., Kaspers, S., George, J. T., Zwiener, I., Zinman, B., Wanner, C., Marx, N., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002492 · Cited by 25
Minutolo, R., Gabbai, F. B., Agarwal, R., Garofalo, C., Borrelli, S., Chiodini, P., Signoriello, S., Paoletti, E., Ravera, M., Bellizzi, V., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab017 · Cited by 25
Lee, H., Lee, H., Townsend, R. R., Kim, D. W., Park, S., & Kim, H. C. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.040 · Cited by 24
Ghazi, L., COHEN, L. P., Muntner, P., Shimbo, D., & Drawz, P. E. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15300 · Cited by 23
Lee, J. Y., Park, J. T., Joo, Y. S., Lee, C., Yun, H., Chang, T. I., Kim, Y.-H., Chung, W., Yoo, T., Kang, S., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab257 · Cited by 20
Teo, Y. H., Chia, A. Z. Q., Teo, Y. N., Chong, E. Y., Syn, N. L. X., Cheong, J. Y. A., Ong, H. T., Wee, C. F., Ting, A. Z. H., Tan, J. T. A., et al. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003280 · Cited by 18
What Is the Hypertension “Phenotype”?
Burnier, M., & Wuerzner, G. (2015) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-015-0438-5 · Cited by 5
Self-citationMielke, J., Trucks-Jansen, H., Schurmann, C., Kotsis, F., Köttgen, A., Schneider, M. P., Eckardt, K., GCKD Investigators, Kotsis, F., Köttgen, A., et al. (2022) · Journal of Human Hypertension · doi:10.1038/s41371-022-00701-0 · Cited by 5
Tsuchimoto, A., Tanaka, S., Kitamura, H., Hiyamuta, H., Tsuruya, K., Kitazono, T., Nakano, T., Fujimi, S., Hirakata, H., Hirano, T., et al. (2022) · Clinical and Experimental Nephrology · doi:10.1007/s10157-022-02250-9 · Cited by 3
Metadata
- Authors
- Burnier, M., & Damianaki, A.
- Venue
- Circulation Research
- Published
- 2023-04-14
- Volume
- 132
- Issue
- 8
- Pages
- 1050-1063
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W4365445818
- Cited by
- 400
- References
- 140
- FWCI
- 70.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.